Researchers Develop Antibody to Fight Colorectal Cancer
An engineered anti‑DKK2 antibody suppresses tumor growth in colorectal cancer models by restoring immune function.
Yale researchers engineered an anti‑DKK2 antibody that blocks tumor growth in colorectal cancer models by inhibiting DKK2, a Wnt pathway antagonist, thereby restoring immune responses and enhancing PD‑1 blockade effectiveness.
Targeting DKK2 could overcome resistance to existing immunotherapies, providing a novel therapeutic option for colorectal cancer patients and potentially other resistant cancers.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics